Sofinnova Partners Raises $200M Digital Medicine Fund
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the successful close of Sofinnova Digital Medicine I at $200 million (€190M), significantly exceeding its target. The fund, spearheaded by Partners Edward Kliphuis and Simon Turner, is dedicated to backing pioneering entrepreneurs navigating the convergence of biology, data, and computation, and has already made investments into five revolutionary companies since its inception.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231025313997/en/
Edward Kliphuis, Partner, Sofinnova Digital Medicine Strategy and Simon Turner, Partner, Sofinnova Digital Medicine Strategy (Photo: Sofinnova Partners)
Antoine Papiernik, Sofinnova’s Chairman and Managing Partner, said: “The successful closing of Sofinnova Digital Medicine I above its target size marks yet another milestone in our growth as a global firm fostering disruptive innovations in life sciences. This newest fund in our platform of investment strategies is a testament to the trust our limited partners place in our vision and to Sofinnova’s longstanding commitment to shaping the future of healthcare.”
Sofinnova’s Digital Medicine Strategy comes at a pivotal moment when the healthcare sector is undergoing a significant transformation, aided by digital advancements. The fund targets three main areas: enabling technologies, analytics, and treatment. It provides entrepreneurs with financial backing, expertise, and deeply-rooted healthcare networks, empowering them to address global healthcare challenges and enhance patient outcomes worldwide.
The two most recent additions to the Sofinnova Digital Medicine portfolio include:
- L’école AI, creator of a “machine teaching” technology and established by an ex-Twitter Cortex founding team member, simplifies the deployment of deep-learning systems for computer vision in life sciences applications.
- Betteromics, the “Omics AI Cloud,” unifies disparate health and omics data into a single source of truth through a certified SaaS platform, backed by the expertise of its founding team from GRAIL, Verily and Google's Search Knowledge Graph.
Edward Kliphuis, Partner, said: “In just a few months since launching this strategy, we've executed five investments into transformative companies, including Kiro, BioCorteX, deepc, L’école AI, and Betteromics, which are fusing state-of-the-art computational methods with advanced biological innovations. Leveraging Sofinnova’s expertise and network, we serve as allies to digital medicine pioneers, enabling them to secure product-market fit and scale on a global stage.”
Simon Turner, Partner, said: “We bring Sofinnova’s deep healthcare expertise to entrepreneurs pioneering at the forefront of digital medicine where biology meets tech-industry approaches like rapid product iteration and accelerated commercialization. Our goal is to support innovators developing disruptive solutions for patients and health systems.”
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231025313997/en/
Contact information
Bommy Lee
Head of Communications
Sofinnova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
North America
RooneyPartners LLC
Kate Barrette
kbarrette@rooneypartners.com
+1 212 223 0561
United Kingdom
Optimum Strategic Communications
Hana Malik
sofinnova@optimumcomms.com
+44 (0) 20 3922 0900
France
StrategiesImage
Anne Rein
anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05
Italy
Havas PR Milan
Pierluigi Cavarai
pierluigi.cavaraiext@havaspr.com
+39 (0) 392 77 999 33
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KIOXIA and Linus Media Group Set World Record for Pi Calculation19.5.2025 09:00:00 EEST | Press release
Kioxia Corporation, a world leader in memory solutions, today announced that it has collaborated with Linus Media Group, creator of Linus Tech Tips and other influential technology-focused YouTubeTM channels, to set a new GUINNESS WORLD RECORDS® title for the Most Accurate Value of Pi. A groundbreaking 300 trillion digits were calculated and have been officially verified and confirmed by Guinness World Records1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250518801709/en/ KIOXIA SSD The record-smashing computation was enabled by a high-performance storage cluster comprising 2.2 petabytes (PB)2 of 30.72 terabyte (TB) CM Series and 15.36 TB CD Series PCIe® NVMe™-based solid-state drives (SSDs) from KIOXIA. These SSDs were configured in a network-attached storage environment connected to a dual-CPU compute server and ran for nearly seven and a half months. Pi (π) represents the mathematical constant expressing the ratio of a
NetApp Builds AI Infrastructure on NVIDIA AI Data Platform19.5.2025 09:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that it is working with NVIDIA to support the NVIDIA AI Data Platform reference design in the NetApp AIPod solution to accelerate enterprise adoption of agentic AI. Powered by the robust and mature data management capabilities of NetApp ONTAP®, NetApp AIPod deployments built on the NVIDIA AI Data Platform will help businesses build secure, governed, and scalable AI data pipelines for retrieval-augmented generation (RAG) and inferencing, enabling organizations to harness the full potential of AI innovation. As businesses invest in AI to solve complex business challenges, they need intelligent data infrastructure that can remove the data silos that slow technical innovation. The most recent NetApp Data Complexity report found that 79 percent of tech and business leaders agree that unifying their data estates is critical for achieving top AI outcomes in 2025. As a NVIDIA-Certified Storage partner leveragi
Fujirebio Receives Marketing Clearance for Lumipulse ® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease17.5.2025 09:58:00 EEST | Press release
Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid to identify patients with amyloid pathology associated with Alzheimer’s Disease (AD). Alzheimer’s disease currently affects an estimated 7.2 million Americans, a number projected to rise to nearly 14 million by 2060.1 It is a leading cause of disability and death. AD develops over many years, long before symptoms are evident, but the lack of accessible, minimally invasive diagnostics results in many patients remaining undiagnosed until the disease is well advanced, when few effective interventions remain. The Lumipulse G pT
IFF Announces Pricing of Tender Offers For Certain Outstanding Series of Notes17.5.2025 00:17:00 EEST | Press release
IFF (NYSE: IFF) announced today the Total Consideration (as defined below) payable in connection with its previously announced tender offers to purchase for cash: (i) up to $1,100,000,000 aggregate purchase price, excluding accrued and unpaid interest (the “Amended Pool 1 Maximum Amount”), of its 1.230% Senior Notes due 2025 (the “2025 Notes”), 1.832% Senior Notes due 2027 (the “2027 Notes”), 4.450% Senior Notes due 2028 (the “2028 Notes”) and 2.300% Senior Notes due 2030 (the “2030 Notes” and collectively with the 2025 Notes, the 2027 Notes and the 2028 Notes, the “Pool 1 Notes”) and (ii) up to $900,000,000 aggregate purchase price, excluding accrued and unpaid interest (the “Amended Pool 2 Maximum Amount” and, together with the Amended Pool 1 Maximum Amount, the “Amended Maximum Amounts”), of its 3.268% Senior Notes due 2040 (the “2040 Notes”), 4.375% Senior Notes due 2047 (the “2047 Notes”), 5.000% Senior Notes due 2048 (the “2048 Notes”) and 3.468% Senior Notes due 2050 (the “2050
Origins Launches in the U.S. Amazon Premium Beauty Store16.5.2025 16:00:00 EEST | Press release
Origins, with over 30 years of expertise in combining naturally-derived and scientifically crafted ingredients for powerful skincare, announced its official debut in the U.S. Amazon Premium Beauty store today. Origins will offer its iconic skincare and body care products along with giftable sets that are perfect for any occasion. Origins will now bring naturally-derived, effective beauty to Amazon customers nationwide with convenience and thoughtful gifting in mind. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250516435958/en/ This launch marks a strategic step in Origins’ ongoing efforts to meet the evolving needs of skincare shoppers, seeking high-performance, conscious beauty on their favorite platforms. By expanding to the U.S. Amazon Premium Beauty store, Origins reinforces its commitment to delivering both efficacy and accessibility to even more consumers. Amazon customers will now be able to discover and purchase Or
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom